The company has shut down the Veris molecular diagnostics product line, which Beckman Coulter spent years developing, as a result of its acquisition of Cepheid.
Alere is divesting Epocal as it seeks regulatory approval of its merger with Abbott. Based in Ottawa, Ontario, Epocal develops point-of-care blood diagnostic systems.
Alere is divesting Epocal as it seeks regulatory approval of its merger with Abbott. Based in Ottawa, Ontario, Epocal develops point-of-care blood diagnostic systems.
This application note demonstrates the use of Enzo Life Sciences’ POLYVIEW IHC detection reagents and HIGHDEF IHC chromogen with Dako Autostainer Link 48 and Biocare Medical intelliPATH FLX as platforms to stain key biomarkers used in both fundamental and clinical cancer research.
What’s been holding back more widespread adoption of liquid biopsy testing?
Lack of adequate circulating tumor DNA reference materials for developing and measuring safe, accurate and reproducible assays has been a challenge for clinical labs
Liquid biopsies are poised to revolutionize cancer diagnosis and therapy, but until now, advances in diagnostic technology - particularly at the low end of the sample input and sensitivity spectrum - have been hampered by the lack of ability of labs to reproducibly measure and assess the assay’s performance.
Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.
That goal is within reach. And in this paper, we’ll show you how. By reading this white paper, you will learn:
· Why quality control is so challenging for NGS labs
· How reference materials may be the key to quality control
· The 9 key characteristics of sufficient NGS reference materials
· How to use QC metrics to monitor the health of your NGS assays
